← Leaderboards
Haizhen Wang
Medical University Of South Carolina
$1,873,394
Attributed
$1,873,394
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $345.4K · FY2020–25$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,873,394 · 2
By mechanism
R37$1,701,837 · 1
P20$171,557 · 1
Top collaborators
No co-investigators on record.
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Daohong Zhou$16,846,361
- Mark P Rubinstein$2,818,767
- John M. Wrangle$2,019,783
- Paul J Nietert$3,999,082
- Thomas W Gettys$21,608,331
Others in their field
Other Emerging Leaders on “Cyclin D3”
- John Sing Choy · Catholic University Of America$473,458
- Masako Nakanishi · University Of Connecticut Sch Of Med/Dnt$417,085
- Brad Reinholt · Icahn School Of Medicine At Mount Sinai$35,666
Research focus
Cyclin D3EnzymesAcute T Cell LeukemiaGlycolysisApoptosisCyclin-Dependent Kinase 6PlayT-LymphocyteCellsCell ProliferationAnti-Pd-L1Cancer InvasivenessCorrelative StudyCancer CellBlood PlateletsAntibodiesCyclin D1Cxcr4 ReceptorsBindingChemokine ReceptorC-Myc GenesCohortCell NucleusCell Line
Grant awards (6)
Novel functions of CDK6 in T-cell leukemia progression$345,413
R37 · FY2025 · CA · contact PI
Novel functions of CDK6 in T-cell leukemia progression$328,143
R37 · FY2024 · CA · contact PI
Novel functions of CDK6 in T-cell leukemia progression$338,504
R37 · FY2023 · CA · contact PI
Novel functions of CDK6 in T-cell leukemia progression$345,413
R37 · FY2022 · CA · contact PI
Novel functions of CDK6 in T-cell leukemia progression$344,364
R37 · FY2021 · CA · contact PI
Functional study of cyclin D3/CDK6 in regulating T-ALL progression via tumor cellular ROS and T cell$171,557
P20 · FY2020 · GM · contact PI